October 31, 2017, Adlai Nortye entered into collaboration and co-development with Institute of Materia Medica(IMM), Chinese Academy of Medical Sciences & Peking Union Medical College, for exclusive global rights to develop and commercialize of PD-1/L1 small molecular inhibitor. According to the agreement, two parties will collaborate in preclinical development, investigational new drug (IND), clinical development and new drug application (NDA). The IND is anticipated to be filed with the U.S. Food and Drug Administration (FDA) and China Food and Drug Administration (CFDA) in the calendar year 2019.
About Adlai Nortye
Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs. We focus on building a specialty therapeutics mainly in discovering and developing important new treatments for cancer and bolic diseases. Our mission is to improve patient lives by identifying and acquiring differentiated innovative medicines that help people feel better, live longer. We have 18 patents granted and 6 PCT published. Based on the successful experience in peptide and protein drugs, we have expanded our expertise into small molecules and therapeutic antibodies. With cooperation with global partners, we have successfully positioned in an exciting area of immuno-oncology and bolic diseases, and several related projects is being proceed well.
The Institute of Materia Medica (IMM), Chinese
Academy of Medical Sciences & Peking Union Medical College was founded in 1958. Its mandate is to
discover and research innovative drugs for treating or preventing human
diseases. IMM’s scientists use the latest biomedical theories, cutting-edge
technologies, and state-of-the-art equipment to develop drugs from botanical
compounds, synthetic chemicals, and biologicals.